Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

‘another explosion outside Kabul airport’ -Tweet From Israeli Public Broadcasting Reporter

https://twitter.com/AmichaiStein1/status/1430979875058429953

byBenzinga Newsdesk

August 26, 2021

1 minute read

#BREAKING: another explosion outside Kabul airport

— Amichai Stein (@AmichaiStein1) August 26, 2021

Medigus Board Of Directors Decides Promotes $2M Buyback Program

By Benzinga Newsdesk

Today, 8:35 AM

Medigus Ltd. (NASDAQ:MDGS), a technology company engaged in advanced medical solutions, innovative internet technologies and electric vehicle and charging solutions, today announced its board of directors authorized the

MDGS

M&A
News

Rio Tinto Offers To Buy Turquoise Hill Resources For $2.7B: Reuters

By Akanksha Bakshi

Today, 8:35 AM

Rio Tinto plc (NYSE:RIO) proposed to buy out Turquoise Hill Resources Ltd (NYSE:TRQ) for $2.7 billion, aiming to gain more control…

RIO

JMP Securities Maintains Market Outperform on Taysha Gene Therapies, Lowers Price Target to $4

By Benzinga Newsdesk

Today, 8:35 AM

JMP Securities analyst Silvan Tuerkcan maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Market Outperform and lowers the price target from $6 to $4.

TSHA

Here’s How Much $100 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth Today

By Benzinga Insights

Today, 8:35 AM

CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 13.48% on an annualized basis producing an average annual return of 21.37%. Currently, CRISPR Therapeutics has a market capitalization of $3.89 billion.

CRSP

‘another explosion outside Kabul airport’ -Tweet From Israeli Public Broadcasting Reporter

Related Posts

Medigus Board Of Directors Decides Promotes $2M Buyback Program

Rio Tinto Offers To Buy Turquoise Hill Resources For $2.7B: Reuters

JMP Securities Maintains Market Outperform on Taysha Gene Therapies, Lowers Price Target to $4

Here’s How Much $100 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth Today